دورية أكاديمية
Real-World Outcomes of a Loading Phase with Intravitreal Faricimab in Neovascular Age-Related Macular Degeneration (n-AMD) and Diabetic Macular Edema (DME)
| العنوان: | Real-World Outcomes of a Loading Phase with Intravitreal Faricimab in Neovascular Age-Related Macular Degeneration (n-AMD) and Diabetic Macular Edema (DME) |
|---|---|
| المؤلفون: | Ermete Giancipoli, Antonella Guglielmi, Anna Valeria Bux, Giulia Maria Emilia Clima, Francesco Pignatelli, Francesco Boscia, Pasquale Viggiano, Giacomo Boscia, Francesca Fortunato, Gianluca Besozzi, Alfredo Niro, Stefano Dore, Cristiana Iaculli |
| المصدر: | Ophthalmology and Therapy, Vol 13, Iss 8, Pp 2163-2184 (2024) |
| بيانات النشر: | Adis, Springer Healthcare, 2024. |
| سنة النشر: | 2024 |
| المجموعة: | LCC:Ophthalmology |
| مصطلحات موضوعية: | Faricimab, Dual inhibition, Anti-vascular endothelial growth factor (anti-VEGF), Neovascular age-related macular degeneration (n-AMD), Diabetic macular edema (DME), Biomarkers, Ophthalmology, RE1-994 |
| الوصف: | Abstract Introduction The aims of this work were to evaluate the real-world efficacy and safety of a loading dose of intravitreal faricimab in eyes with active neovascular age-related macular degeneration (n-AMD) or diabetic macular edema (DME) and to analyze the treatment outcome in relation to specific biomarkers. Methods Patients with active n-AMD or DME, treated with four monthly intravitreal injections of faricimab, were enrolled in this retrospective, uncontrolled study. Best-corrected visual acuity (BCVA), central subfield thickness (CST), presence of retinal fluid (RF) on optical coherence tomography (OCT), and adverse events were assessed at baseline and at weeks 4, 8, 12, and 16. Predefined biomarkers were evaluated at baseline (BL) and at last visit. Results Sixteen eyes of 15 patients with n-AMD (n-AMD group) and 15 eyes of 12 patients with DME (DME group) were included. Mean (± standard deviation) logarithm of minimum angle of resolution (logMAR) BL BCVA changed from 0.68 (± 0.43) to 0.53 (± 0.36; P = 0.13) and from 0.51 (± 0.34) to 0.32 (± 0.24; P: 0.048) at week 16 in n-AMD and DME group, respectively. A statistically significant mean CST reduction was reported in both groups at last visit (n-AMD: − 166.5 μm; P = 0.0009/DME: − 110.8 μm; P = 0.0086). Seventy-five and 33% of eyes with n-AMD and DME respectively achieved complete RF resolution at last visit. Subfoveal inner and outer retinal damage correlated with a lower final BCVA in n-AMD group. The presence of large (> 100 μm) juxtafoveal microaneurysms (MAs) was significantly correlated with a higher chance of residual fluid in eyes with DME. Conclusions Both n-AMD and DME groups achieved satisfactory anatomical results after a loading-dose of intravitreal faricimab. BCVA improvement might be hampered by pre-existing retinal damage in eyes with n-AMD. Large, juxtafoveal MAs might represent a hallmark of a slower anatomical response to the treatment in eyes with DME. |
| نوع الوثيقة: | article |
| وصف الملف: | electronic resource |
| اللغة: | English |
| تدمد: | 2193-8245 2193-6528 |
| Relation: | https://doaj.org/toc/2193-8245; https://doaj.org/toc/2193-6528 |
| DOI: | 10.1007/s40123-024-00980-5 |
| URL الوصول: | https://doaj.org/article/44b331a85ec34edd8a601ea598a68726 |
| رقم الأكسشن: | edsdoj.44b331a85ec34edd8a601ea598a68726 |
| قاعدة البيانات: | Directory of Open Access Journals |
Find this article in full text from Springer Verlag. 
Full Text Finder | تدمد: | 21938245 21936528 |
|---|---|
| DOI: | 10.1007/s40123-024-00980-5 |